Are Our Type 2 Diabetes Patients Sufficiently Protected from Cardiorenal Complications?

Goh Su-Yen

The Singapore Family Physician

Back to issue Vol 47 No. 8 - Updates in DM and CKD management: Are SGLT2 Inhibitors the answer?

Are Our Type 2 Diabetes Patients Sufficiently Protected from Cardiorenal Complications?

Full text:

View PDF or right-click to save

Author(s):

Goh Su-Yen

Published in:

The Singapore Family Physician Vol 47 No 8 - Updates in DM and CKD management: Are SGLT2 Inhibitors the answer?

Page(s):

5 - 8

Publication date:

1 October 2021

ISSN:

0377-5305

Abstract

Cardiovascular and renal outcome trials categorically demonstrate the benefits of SGLT2 inhibitors (SGLT2i). Various pharmacotherapy algorithms recommend early use of SGLT2i, especially among those with existing cardiovascular disease, heart failure, or kidney disease. Despite a widening spectrum of patient eligibility, treatment gaps and clinical inertia still exist.